We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
140
Reports published
10k+
Readers in database
#FUM #DermaSys was effective by all measures in the FM57 study, both with AND w/out addition of GTN. Dose-dependent safety allays fears re formulation/admin errors. FDA/EMA discussions to confirm next steps: simpler & quicker medical device route likely https://t.co/If0GxKR8jS
.@BGenBio presented more encouraging data from the Phase II trial in AML with bemcentinib in combination with LDAC at #ASH19, read our views on the data at https://t.co/EKP4X2qE6d
Unprecedented results from #FuturaMedical FM57 #erectiledysfunction study; all doses hit all primary endpoints vs baseline at 12 wks (p<0.001), but no differentiation between any active arms (MED2005) & placebo (DermaSys alone)
Read our $FUM Update at: https://t.co/If0GxKR8jS
Publication of @BONESUPPORT_AB's #CERAMENT #CERTiFy data in @jbjs provides impetus to increased market share of bone graft market, potentially shifting standard of care $BONEX 1/2
A new player in the #diabetes space? @arecor_ltd has reported positive headline results from the Phase I trial with its ultra-rapid acting insulin AT247, which was found to have a favourable PK/PD profile compared to @novonordisk's NovoRapid and Fiasp.
https://t.co/lhLz1wwJdA
Fifth commercial licence deal of the year for @MaxCyte_info MaxCyte following the agreement with @KSQ_TX for its eTIL products. Read our Lighthouse note at https://t.co/CUlssaOCce
Please sign up here to be added to our distribution database
